Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 125 entries
Sorted by: Best Match Show Resources per page
Vaccine impact and effectiveness of meningococcal serogroup ACWY conjugate vaccine implementation in the Netherlands: a nationwide surveillance study.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Ohm M, Hahné SJM, van der Ende A, Sanders EAM, Berbers GAM, Ruijs WLM, van Sorge NM, de Melker HE, Knol MJ.
PMID: 34525199
Clin Infect Dis. 2021 Sep 15; doi: 10.1093/cid/ciab791. Epub 2021 Sep 15.

BACKGROUND: In response to the recent serogroup W invasive meningococcal disease (IMD-W) epidemic in the Netherlands, meningococcal serogroup C (MenC) conjugate vaccination for 14-month-olds was replaced with a MenACWY conjugate vaccination, and a mass campaign targeting 14-18 year-olds was...

Cite
Ohm M, Hahné SJM, van der Ende A, et al. Vaccine impact and effectiveness of meningococcal serogroup ACWY conjugate vaccine implementation in the Netherlands: a nationwide surveillance study. Clin Infect Dis. 2021;doi: 10.1093/cid/ciab791.
Ohm, M., Hahné, S. J. M., van der Ende, A., Sanders, E. A. M., Berbers, G. A. M., Ruijs, W. L. M., van Sorge, N. M., de Melker, H. E., & Knol, M. J. (2021). Vaccine impact and effectiveness of meningococcal serogroup ACWY conjugate vaccine implementation in the Netherlands: a nationwide surveillance study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, . https://doi.org/10.1093/cid/ciab791
Ohm, Milou, et al. "Vaccine impact and effectiveness of meningococcal serogroup ACWY conjugate vaccine implementation in the Netherlands: a nationwide surveillance study." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America vol. (2021). doi: https://doi.org/10.1093/cid/ciab791
Ohm M, Hahné SJM, van der Ende A, Sanders EAM, Berbers GAM, Ruijs WLM, van Sorge NM, de Melker HE, Knol MJ. Vaccine impact and effectiveness of meningococcal serogroup ACWY conjugate vaccine implementation in the Netherlands: a nationwide surveillance study. Clin Infect Dis. 2021 Sep 15; doi: 10.1093/cid/ciab791. Epub 2021 Sep 15. PMID: 34525199.
Copy Download .nbib Format: NLM
Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe.

Emerging infectious diseases

Hanquet G, Krizova P, Dalby T, Ladhani SN, Nuorti JP, Danis K, Mereckiene J, Knol MJ, Winje BA, Ciruela P, de Miguel S, Portillo ME, MacDonald L, Morfeldt E, Kozakova J, Valentiner-Branth P, Fry NK, Rinta-Kokko H, Varon E, Corcoran M, van der Ende A, Vestrheim DF, Munoz-Almagro C, Sanz JC, Castilla J, Smith A, Henriques-Normark B, Colzani E, Pastore-Celentano L, Savulescu C.
PMID: 34932457
Emerg Infect Dis. 2022 Jan;28(1):137-138. doi: 10.3201/eid2801.210734.

We evaluated invasive pneumococcal disease (IPD) during 8 years of infant pneumococcal conjugate vaccine (PCV) programs using 10-valent (PCV10) and 13-valent (PCV13) vaccines in 10 countries in Europe. IPD incidence declined during 2011-2014 but increased during 2015-2018 in all...

Cite
Hanquet G, Krizova P, Dalby T, et al. Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe. Emerg Infect Dis. 2022;28(1):137-138doi: 10.3201/eid2801.210734.
Hanquet, G., Krizova, P., Dalby, T., Ladhani, S. N., Nuorti, J. P., Danis, K., Mereckiene, J., Knol, M. J., Winje, B. A., Ciruela, P., de Miguel, S., Portillo, M. E., MacDonald, L., Morfeldt, E., Kozakova, J., Valentiner-Branth, P., Fry, N. K., Rinta-Kokko, H., Varon, E., Corcoran, M., van der Ende, A., Vestrheim, D. F., Munoz-Almagro, C., Sanz, J. C., Castilla, J., Smith, A., Henriques-Normark, B., Colzani, E., Pastore-Celentano, L., Savulescu, C. (2022). Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe. Emerging infectious diseases, 28(1), 137-138. https://doi.org/10.3201/eid2801.210734
Hanquet, Germaine, et al. "Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe." Emerging infectious diseases vol. 28,1 (2022): 137-138. doi: https://doi.org/10.3201/eid2801.210734
Hanquet G, Krizova P, Dalby T, Ladhani SN, Nuorti JP, Danis K, Mereckiene J, Knol MJ, Winje BA, Ciruela P, de Miguel S, Portillo ME, MacDonald L, Morfeldt E, Kozakova J, Valentiner-Branth P, Fry NK, Rinta-Kokko H, Varon E, Corcoran M, van der Ende A, Vestrheim DF, Munoz-Almagro C, Sanz JC, Castilla J, Smith A, Henriques-Normark B, Colzani E, Pastore-Celentano L, Savulescu C. Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe. Emerg Infect Dis. 2022 Jan;28(1):137-138. doi: 10.3201/eid2801.210734. PMID: 34932457.
Copy Download .nbib Format: NLM
A Scoping Review of Pharmacy Preceptor Training Programs.

American journal of pharmaceutical education

Knott GJ, Mylrea MF, Glass BD.
PMID: 33149332
Am J Pharm Educ. 2020 Oct;84(10):ajpe8039. doi: 10.5688/ajpe8039.

No abstract available.

Cite
Knott GJ, Mylrea MF, Glass BD. A Scoping Review of Pharmacy Preceptor Training Programs. Am J Pharm Educ. 2020;84(10):ajpe8039doi: 10.5688/ajpe8039.
Knott, G. J., Mylrea, M. F., & Glass, B. D. (2020). A Scoping Review of Pharmacy Preceptor Training Programs. American journal of pharmaceutical education, 84(10), ajpe8039. https://doi.org/10.5688/ajpe8039
Knott, Gillian J, et al. "A Scoping Review of Pharmacy Preceptor Training Programs." American journal of pharmaceutical education vol. 84,10 (2020): ajpe8039. doi: https://doi.org/10.5688/ajpe8039
Knott GJ, Mylrea MF, Glass BD. A Scoping Review of Pharmacy Preceptor Training Programs. Am J Pharm Educ. 2020 Oct;84(10):ajpe8039. doi: 10.5688/ajpe8039. PMID: 33149332; PMCID: PMC7596604.
Copy Download .nbib Format: NLM
Seroprevalence of meningococcal ACWY antibodies across the population in the Netherlands: Two consecutive surveys in 2016/17 and 2020.

Vaccine

Ohm M, Knol MJ, Vos ERA, Bogaard MJM, van Rooijen DM, Sanders EAM, de Melker HE, van der Klis FRM, Berbers GAM.
PMID: 34839991
Vaccine. 2022 Jan 03;40(1):59-66. doi: 10.1016/j.vaccine.2021.11.045. Epub 2021 Nov 25.

BACKGROUND: Meningococcal serogroup C (MenC) vaccination was introduced for 14-month-olds in the Netherlands in 2002, alongside a mass campaign for 1-18 year-olds. Due to an outbreak of serogroup W disease, MenC vaccination was replaced for MenACWY vaccination in 2018,...

Cite
Ohm M, Knol MJ, Vos ERA, et al. Seroprevalence of meningococcal ACWY antibodies across the population in the Netherlands: Two consecutive surveys in 2016/17 and 2020. Vaccine. 2021;40(1):59-66doi: 10.1016/j.vaccine.2021.11.045.
Ohm, M., Knol, M. J., Vos, E. R. A., Bogaard, M. J. M., van Rooijen, D. M., Sanders, E. A. M., de Melker, H. E., van der Klis, F. R. M., & Berbers, G. A. M. (2022). Seroprevalence of meningococcal ACWY antibodies across the population in the Netherlands: Two consecutive surveys in 2016/17 and 2020. Vaccine, 40(1), 59-66. https://doi.org/10.1016/j.vaccine.2021.11.045
Ohm, Milou, et al. "Seroprevalence of meningococcal ACWY antibodies across the population in the Netherlands: Two consecutive surveys in 2016/17 and 2020." Vaccine vol. 40,1 (2022): 59-66. doi: https://doi.org/10.1016/j.vaccine.2021.11.045
Ohm M, Knol MJ, Vos ERA, Bogaard MJM, van Rooijen DM, Sanders EAM, de Melker HE, van der Klis FRM, Berbers GAM. Seroprevalence of meningococcal ACWY antibodies across the population in the Netherlands: Two consecutive surveys in 2016/17 and 2020. Vaccine. 2022 Jan 03;40(1):59-66. doi: 10.1016/j.vaccine.2021.11.045. Epub 2021 Nov 25. PMID: 34839991.
Copy Download .nbib Format: NLM
Half-dose glucarpidase as efficient rescue for toxic methotrexate levels in patients with acute kidney injury.

Cancer chemotherapy and pharmacology

Heuschkel S, Kretschmann T, Teipel R, von Bonin S, Richter S, Quick S, Alakel N, Röllig C, Balaian E, Kroschinsky F, Knoth H, Bornhäuser M, von Bonin M.
PMID: 34669022
Cancer Chemother Pharmacol. 2022 Jan;89(1):41-48. doi: 10.1007/s00280-021-04361-8. Epub 2021 Oct 20.

PURPOSE: High-dose methotrexate (HDMTX)-associated acute kidney injury with delayed MTX clearance has been linked to an excess in MTX-induced toxicities. Glucarpidase is a recombinant enzyme that rapidly hydrolyzes MTX into non-toxic metabolites. The recommended dose of glucarpidase is 50...

Cite
Heuschkel S, Kretschmann T, Teipel R, et al. Half-dose glucarpidase as efficient rescue for toxic methotrexate levels in patients with acute kidney injury. Cancer Chemother Pharmacol. 2021;89(1):41-48doi: 10.1007/s00280-021-04361-8.
Heuschkel, S., Kretschmann, T., Teipel, R., von Bonin, S., Richter, S., Quick, S., Alakel, N., Röllig, C., Balaian, E., Kroschinsky, F., Knoth, H., Bornhäuser, M., & von Bonin, M. (2022). Half-dose glucarpidase as efficient rescue for toxic methotrexate levels in patients with acute kidney injury. Cancer chemotherapy and pharmacology, 89(1), 41-48. https://doi.org/10.1007/s00280-021-04361-8
Heuschkel, Sandra, et al. "Half-dose glucarpidase as efficient rescue for toxic methotrexate levels in patients with acute kidney injury." Cancer chemotherapy and pharmacology vol. 89,1 (2022): 41-48. doi: https://doi.org/10.1007/s00280-021-04361-8
Heuschkel S, Kretschmann T, Teipel R, von Bonin S, Richter S, Quick S, Alakel N, Röllig C, Balaian E, Kroschinsky F, Knoth H, Bornhäuser M, von Bonin M. Half-dose glucarpidase as efficient rescue for toxic methotrexate levels in patients with acute kidney injury. Cancer Chemother Pharmacol. 2022 Jan;89(1):41-48. doi: 10.1007/s00280-021-04361-8. Epub 2021 Oct 20. PMID: 34669022.
Copy Download .nbib Format: NLM
Onset of sliding friction in incommensurate systems.

Physical review letters

Consoli L, Knops HJ, Fasolino A.
PMID: 10991268
Phys Rev Lett. 2000 Jul 10;85(2):302-5. doi: 10.1103/PhysRevLett.85.302.

We study the dynamics of an incommensurate chain sliding on a periodic lattice, modeled by the Frenkel-Kontorova Hamiltonian with initial kinetic energy, without damping and driving terms. We show that the onset of friction is due to a novel...

Cite
Consoli L, Knops HJ, Fasolino A. Onset of sliding friction in incommensurate systems. Phys Rev Lett. 2000;85(2):302-5doi: 10.1103/PhysRevLett.85.302.
Consoli, L., Knops, H. J., & Fasolino, A. (2000). Onset of sliding friction in incommensurate systems. Physical review letters, 85(2), 302-5. https://doi.org/10.1103/PhysRevLett.85.302
Consoli, et al. "Onset of sliding friction in incommensurate systems." Physical review letters vol. 85,2 (2000): 302-5. doi: https://doi.org/10.1103/PhysRevLett.85.302
Consoli L, Knops HJ, Fasolino A. Onset of sliding friction in incommensurate systems. Phys Rev Lett. 2000 Jul 10;85(2):302-5. doi: 10.1103/PhysRevLett.85.302. PMID: 10991268.
Copy Download .nbib Format: NLM
Tunneling versus thermionic emission in one-dimensional semiconductors.

Physical review letters

Appenzeller J, Radosavljević M, Knoch J, Avouris P.
PMID: 14995412
Phys Rev Lett. 2004 Jan 30;92(4):048301. doi: 10.1103/PhysRevLett.92.048301. Epub 2004 Jan 28.

This Letter focuses on the role of contacts and the influence of Schottky barriers on the switching in nanotransistors. Specifically, we discuss (i) the mechanism for injection from a three-dimensional metal into a low-dimensional semiconductor, i.e., the competition between...

Cite
Appenzeller J, Radosavljević M, Knoch J, et al. Tunneling versus thermionic emission in one-dimensional semiconductors. Phys Rev Lett. 2004;92(4):048301doi: 10.1103/PhysRevLett.92.048301.
Appenzeller, J., Radosavljević, M., Knoch, J., & Avouris, P. (2004). Tunneling versus thermionic emission in one-dimensional semiconductors. Physical review letters, 92(4), 048301. https://doi.org/10.1103/PhysRevLett.92.048301
Appenzeller, J, et al. "Tunneling versus thermionic emission in one-dimensional semiconductors." Physical review letters vol. 92,4 (2004): 048301. doi: https://doi.org/10.1103/PhysRevLett.92.048301
Appenzeller J, Radosavljević M, Knoch J, Avouris P. Tunneling versus thermionic emission in one-dimensional semiconductors. Phys Rev Lett. 2004 Jan 30;92(4):048301. doi: 10.1103/PhysRevLett.92.048301. Epub 2004 Jan 28. PMID: 14995412.
Copy Download .nbib Format: NLM
Socioeconomic Status Is Associated With Antibody Levels Against Vaccine Preventable Diseases in the Netherlands.

Frontiers in public health

Hoes J, Boef AGC, Knol MJ, de Melker HE, Mollema L, van der Klis FRM, Rots NY, van Baarle D.
PMID: 30140666
Front Public Health. 2018 Jul 27;6:209. doi: 10.3389/fpubh.2018.00209. eCollection 2018.

No abstract available.

Cite
Hoes J, Boef AGC, Knol MJ, et al. Socioeconomic Status Is Associated With Antibody Levels Against Vaccine Preventable Diseases in the Netherlands. Front Public Health. 2018;6:209doi: 10.3389/fpubh.2018.00209.
Hoes, J., Boef, A. G. C., Knol, M. J., de Melker, H. E., Mollema, L., van der Klis, F. R. M., Rots, N. Y., & van Baarle, D. (2018). Socioeconomic Status Is Associated With Antibody Levels Against Vaccine Preventable Diseases in the Netherlands. Frontiers in public health, 6209. https://doi.org/10.3389/fpubh.2018.00209
Hoes, Joske, et al. "Socioeconomic Status Is Associated With Antibody Levels Against Vaccine Preventable Diseases in the Netherlands." Frontiers in public health vol. 6 (2018): 209. doi: https://doi.org/10.3389/fpubh.2018.00209
Hoes J, Boef AGC, Knol MJ, de Melker HE, Mollema L, van der Klis FRM, Rots NY, van Baarle D. Socioeconomic Status Is Associated With Antibody Levels Against Vaccine Preventable Diseases in the Netherlands. Front Public Health. 2018 Jul 27;6:209. doi: 10.3389/fpubh.2018.00209. eCollection 2018. PMID: 30140666; PMCID: PMC6094970.
Copy Download .nbib Format: NLM
Evidence Synthesis in Harm Assessment of Medicines Using the Example of Rosiglitazone and Myocardial Infarction.

Frontiers in medicine

Rietbergen C, Stefansdottir G, Leufkens HG, Knol MJ, De Bruin ML, Klugkist I.
PMID: 29520360
Front Med (Lausanne). 2018 Feb 22;4:228. doi: 10.3389/fmed.2017.00228. eCollection 2017.

The current system of harm assessment of medicines has been criticized for relying on intuitive expert judgment. There is a call for more quantitative approaches and transparency in decision-making. Illustrated with the case of cardiovascular safety concerns for rosiglitazone,...

Cite
Rietbergen C, Stefansdottir G, Leufkens HG, et al. Evidence Synthesis in Harm Assessment of Medicines Using the Example of Rosiglitazone and Myocardial Infarction. Front Med (Lausanne). 2018;4:228doi: 10.3389/fmed.2017.00228.
Rietbergen, C., Stefansdottir, G., Leufkens, H. G., Knol, M. J., De Bruin, M. L., & Klugkist, I. (2017). Evidence Synthesis in Harm Assessment of Medicines Using the Example of Rosiglitazone and Myocardial Infarction. Frontiers in medicine, 4228. https://doi.org/10.3389/fmed.2017.00228
Rietbergen, Charlotte, et al. "Evidence Synthesis in Harm Assessment of Medicines Using the Example of Rosiglitazone and Myocardial Infarction." Frontiers in medicine vol. 4 (2017): 228. doi: https://doi.org/10.3389/fmed.2017.00228
Rietbergen C, Stefansdottir G, Leufkens HG, Knol MJ, De Bruin ML, Klugkist I. Evidence Synthesis in Harm Assessment of Medicines Using the Example of Rosiglitazone and Myocardial Infarction. Front Med (Lausanne). 2018 Feb 22;4:228. doi: 10.3389/fmed.2017.00228. eCollection 2017. PMID: 29520360; PMCID: PMC5827152.
Copy Download .nbib Format: NLM
Participation and performance trends in multistage ultramarathons-the 'Marathon des Sables' 2003-2012.

Extreme physiology & medicine

Knoth C, Knechtle B, Rüst CA, Rosemann T, Lepers R.
PMID: 23849138
Extrem Physiol Med. 2012 Dec 01;1(1):13. doi: 10.1186/2046-7648-1-13.

BACKGROUND: The purpose of this study was to investigate participation and performance changes in the multistage ultramarathon 'Marathon des Sables' from 2003 to 2012.METHODS: Participation and performance trends in the four- or six-stage running event covering approximately 250 km...

Cite
Knoth C, Knechtle B, Rüst CA, et al. Participation and performance trends in multistage ultramarathons-the 'Marathon des Sables' 2003-2012. Extrem Physiol Med. 2012;1(1):13doi: 10.1186/2046-7648-1-13.
Knoth, C., Knechtle, B., Rüst, C. A., Rosemann, T., & Lepers, R. (2012). Participation and performance trends in multistage ultramarathons-the 'Marathon des Sables' 2003-2012. Extreme physiology & medicine, 1(1), 13. https://doi.org/10.1186/2046-7648-1-13
Knoth, Christoph, et al. "Participation and performance trends in multistage ultramarathons-the 'Marathon des Sables' 2003-2012." Extreme physiology & medicine vol. 1,1 (2012): 13. doi: https://doi.org/10.1186/2046-7648-1-13
Knoth C, Knechtle B, Rüst CA, Rosemann T, Lepers R. Participation and performance trends in multistage ultramarathons-the 'Marathon des Sables' 2003-2012. Extrem Physiol Med. 2012 Dec 01;1(1):13. doi: 10.1186/2046-7648-1-13. PMID: 23849138; PMCID: PMC3710135.
Copy Download .nbib Format: NLM
Optimizing the identification of mono- and bilayer graphene on multilayer substrates.

Applied optics

Kontis C, Mueller MR, Kuechenmeister C, Kallis KT, Knoch J.
PMID: 22270667
Appl Opt. 2012 Jan 20;51(3):385-9. doi: 10.1364/AO.51.000385.

This work presents an investigation and optimization of the identification of graphene mono- and bilayers on various multilayer substrates. Instead of the mere contrast between substrate and substrate/mono/bilayer systems, weighted color differences are used to obtain optimum visibility. Our...

Cite
Kontis C, Mueller MR, Kuechenmeister C, et al. Optimizing the identification of mono- and bilayer graphene on multilayer substrates. Appl Opt. 2012;51(3):385-9doi: 10.1364/AO.51.000385.
Kontis, C., Mueller, M. R., Kuechenmeister, C., Kallis, K. T., & Knoch, J. (2012). Optimizing the identification of mono- and bilayer graphene on multilayer substrates. Applied optics, 51(3), 385-9. https://doi.org/10.1364/AO.51.000385
Kontis, Christopher, et al. "Optimizing the identification of mono- and bilayer graphene on multilayer substrates." Applied optics vol. 51,3 (2012): 385-9. doi: https://doi.org/10.1364/AO.51.000385
Kontis C, Mueller MR, Kuechenmeister C, Kallis KT, Knoch J. Optimizing the identification of mono- and bilayer graphene on multilayer substrates. Appl Opt. 2012 Jan 20;51(3):385-9. doi: 10.1364/AO.51.000385. PMID: 22270667.
Copy Download .nbib Format: NLM
Monte Carlo transfer-matrix study of the frustrated XY model.

Physical review. B, Condensed matter

Knops HJ, Thijssen JM.
PMID: 9995693
Phys Rev B Condens Matter. 1990 Aug 01;42(4):2438-2444. doi: 10.1103/physrevb.42.2438.

No abstract available.

Cite
Knops HJ, Thijssen JM. Monte Carlo transfer-matrix study of the frustrated XY model. Phys Rev B Condens Matter. 1990;42(4):2438-2444doi: 10.1103/physrevb.42.2438.
Knops, H. J., & Thijssen, J. M. (1990). Monte Carlo transfer-matrix study of the frustrated XY model. Physical review. B, Condensed matter, 42(4), 2438-2444. https://doi.org/10.1103/physrevb.42.2438
Knops, and Thijssen. "Monte Carlo transfer-matrix study of the frustrated XY model." Physical review. B, Condensed matter vol. 42,4 (1990): 2438-2444. doi: https://doi.org/10.1103/physrevb.42.2438
Knops HJ, Thijssen JM. Monte Carlo transfer-matrix study of the frustrated XY model. Phys Rev B Condens Matter. 1990 Aug 01;42(4):2438-2444. doi: 10.1103/physrevb.42.2438. PMID: 9995693.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 125 entries